- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Location Directory
Clinical trials in Birmingham, Alabama
This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9530
Shown on this page
12
Current sort
Recently updated
Location scope
Birmingham, AL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 781–792 of 9,530 matching trials in Birmingham, AL.
Live ClinicalTrials.gov results.
Institutions in Birmingham
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Atopic Dermatitis (AD)
- Interventions
- ENV-294, Placebo
- Drug
- Lead sponsor
- Enveda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation)
- Drug · Radiation
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 60
- States / cities
- Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more
- Conditions
- Kidney Transplantation
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Encinitas, California • Encino, California + 41 more
- Conditions
- Simultaneous Kidney and Pancreas Transplantation
- Interventions
- Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit), Tacrolimus, Mycophenolate mofetil
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
- Conditions
- Kidney Transplant
- Interventions
- Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Interventions
- Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
- Biological · Drug · Procedure
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
- Conditions
- Kidney Transplantation, Renal Transplantation
- Interventions
- Alemtuzumab, MMF, Basiliximab, Short-term Tac, tacrolimus, Belatacept, methylprednisolone
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
- Conditions
- Vasospasm, Cerebral, Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Vectris trial leads and stimulation, Sham
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2031
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Asthma
- Interventions
- ENV-294, Placebo
- Drug
- Lead sponsor
- Enveda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Jose, California + 17 more